Posts on Jan 1970

Prof. Jose Luis Pedraz, new “Académico de Número” of the Spanish Royal National Academy of Pharmacy

Madrid, June, 2024 – In a distinguished ceremony held at the Spanish Royal National Academy of Pharmacy (Real Academia Nacional de Farmacia), Professor Jose Luis Pedraz Muñoz, a prominent figure at the University of the Basque Country, was officially inducted as an “Académico de Número”. The highest position within the Royal National Academy of Pharmacy.

Professor Pedraz, who is also a member of the CIBER-BBN and Director of Unit 10 of NANBIOSIS, took possession of “Medal Number 16”. The honor of becoming an “Académico de Número” is a prestigious recognition, from which there can only be a maximum of 50 members at a time. This acknowledes Professor Pedraz’s significant contributions to the field of pharmaceutical technology. During the event, he delivered an insightful speech titled “3D Printing and Bioprinting in Pharmaceutical Technology.”

3D bioprinting, the future of Pharma

Prof. Pedraz’s speech highlighted one of his most pioneering research areas, 3D printing and bioprinting. Together with his research group, NanoBioCel, Prof. Pedraz leads this field with new cutting-edge initiatives.

This innovative lab, which services are channeled through our Unit 10, offers bioprinting services that enable the creation of three-dimensional structures of organs and tissues, new pharmaceutical forms, micro/nano vesicles, and scaffolding for regenative medicine, to name a few.

This recognition by the Royal National Academy of Pharmacy is not just a personal achievement for Professor Pedraz. It is also a testament to the innovative work being done within NANBIOSIS and CIBER-BBN. His contributions are paving the way for future advancements in pharmaceutical and biomedical research, reinforcing the importance of interdisciplinary collaboration and technological innovation in improving healthcare outcomes.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Prof. Pilar Marco takes helm of CIBER-BBN: Leading the future of Bioengineering, Biomaterials, and Nanomedicine

Barcelona, June 21, 2024 – Prof. Pilar Marco has been appointed as the new head of the Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) thematic area at the Centro de Investigación Biomédica en Red (CIBER). This prestigious appointment was confirmed during the CIBER Governing Board meeting held on June 20, 2024. Prof. Marco succeeds Ramón Martínez, bringing a wealth of expertise and a distinguished track record in biomedical research for more than a decade.

Prof. Marco is a research professor at the Consejo Superior de Investigaciones Científicas (CSIC), specifically at the Institute of Advanced Chemistry of Catalonia (IQAC) in Barcelona. Additionally, she leads the Nanobiotechnology for Diagnosis research group and is the Scientific Director of our Custom Antibody Service, the Unit 2 of NANBIOSIS, as well as the coordinator of the Nanomedicine Research Program at CIBER-BBN.

An expert in antibodies and immunoassays

Recognized as an international authority in antibody-based technologies and the development of immunoassays for diagnostic purposes, Prof. Marco’s impressive academic and research portfolio includes 225 published articles and the supervision of 32 doctoral theses. She has also served as Principal Investigator in 14 European projects and over 20 national projects.

Her contributions to scientific innovation are evident in her dedication to knowledge transfer. Prof. Marco holds 15 patents and has signed 36 contracts with various companies, six of which are for commercial exploitation. Her work aims to bridge the gap between research and practical applications, ultimately improving the quality of life in society.

A new chapter in scientific collaboration

In addition to her role at CIBER-BBN, Prof. Marco coordinates the Strategic Diagnostic Initiative of the PTI+ Global Health and serves on the Technical Committee of the National Center for Certification of Health Products. Her leadership and vision are expected to propel CIBER-BBN into new frontiers of research and development in bioengineering, biomaterials, and nanomedicine.

Joining Prof. Marco in the new leadership appointments are Fernando Artalejo, who will head the CIBER for Epidemiology and Public Health (CIBERESP), and Didac Mauricio, who will lead the CIBER for Diabetes and Associated Metabolic Diseases (CIBERDEM). Together, these appointments mark a significant step forward in CIBER’s mission to advance biomedical research and improve public health.

Prof. Pilar Marco’s vision and expertise are set to drive CIBER-BBN’s mission forward, enhancing its contributions to scientific discovery and the development of cutting-edge biomedical technologies. Her leadership promises to strengthen collaborations and foster innovations that will benefit both the scientific community and society at large.

We congratulate Prof. Marco on her new role and look forward to the remarkable advancements that will undoubtedly emerge under her guidance.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: